Search alternatives:
point decrease » point increase (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1581
-
1582
miR-150-5p inhibition modulates pyroptosis and FoxO3a/ARC signaling in ApoE<sup>-/-</sup> mice.
Published 2025Subjects: -
1583
Therapeutic effects of miR-150-5p inhibition on ox-LDL-induced pyroptosis in RAW264.7 macrophages.
Published 2025Subjects: -
1584
-
1585
-
1586
-
1587
-
1588
-
1589
-
1590
-
1591
-
1592
The expression and localization of the WT and <i>CACNA1C-</i>Q1916R channels in HEK293T cells.
Published 2017“…<p>(A-B) Expression levels of WT and mutant of Ca<sub>V</sub>1.2α1C in the intact cell, membrane fraction and cytoplasmic fraction of the HEK293T cells. …”
-
1593
Increased oxidative stress, viral load and decreased survivability of N2a following RIG-I ablation.
Published 2011“…The mean fluorescence intensities obtained from each group are depicted in the figure. (1-Unstained, 2-Mock-infected; 3-JEV-infected, 4-JEV+Sc-MO, 5-JEV+rMO) (A). Immunoblot analysis to detect JEV NS-5 expression also showed enhancement in JEV+rMO when compared to either JEV-infected or JEV+ScMO groups (B&C). …”
-
1594
-
1595
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
Published 2019“…Participants were randomised to anakinra or to a TNFi (i.e., adalimumab, certolizumab pegol, etanercept, infliximab, or golimumab), and the primary end point was the change in percentage of glycated haemoglobin (HbA1c%) (EudraCT: 2012-005370-62 ClinicalTrial.gov: NCT02236481).…”
-
1596
-
1597
mFIZZ1′ and mFIZZ1 decreased the IL-13 and IL-5 secretion of splenocytes.
Published 2013“…Recombinant mFIZZ1′ and mFIZZ1 expressed with or without hQSOX1b were used at 200 ng/ml. rRa is the bacterial recombinant FIZZ1 (200 ng/ml) from (Peprotech) and PBS is the control. (<b>A</b>) Recombinant mFIZZ1′ and mFIZZ1 co-expressed with hQSOX1b significantly decreased the IL-5 secretion compared to the proteins expressed alone. …”
-
1598
-
1599
-
1600